on Moderna, Inc. (NASDAQ:MRNA)
Moderna Secures $176 Million for mRNA-Based Influenza Vaccine Development
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) has announced a $176 million award through the Rapid Response Partnership Vehicle (RRPV) to expedite the development of mRNA-based pandemic influenza vaccines. This funding, provided by the Biomedical Advanced Research and Development Authority (BARDA), aims to support the late-stage development of a pre-pandemic H5 influenza virus vaccine.
The H5 influenza virus, known for causing severe disease in birds, poses a threat of human transmission. Moderna's project includes further options to prepare and respond to future public health challenges. CEO Stéphane Bancel highlighted the advantages of mRNA technology in addressing infectious diseases, as evidenced during the COVID-19 pandemic.
In 2023, Moderna initiated a Phase 1/2 study to assess the safety and immunogenicity of its mRNA-1018 influenza vaccine in adults. Results are expected in 2024 and will guide Phase 3 plans. This project is federally funded under Other Transaction (OT) number: 75A50123D00005.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Moderna, Inc. news